• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕罗西汀、认知疗法或两者联合治疗伴或不伴回避型人格障碍的社交焦虑障碍:一项随机临床试验。

Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial.

机构信息

Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.

出版信息

Psychother Psychosom. 2016;85(6):346-356. doi: 10.1159/000447013. Epub 2016 Oct 15.

DOI:10.1159/000447013
PMID:27744447
Abstract

BACKGROUND

The most efficacious treatments for social anxiety disorder (SAD) are the SSRIs and cognitive therapy (CT). Combined treatment is advocated for SAD but has not been evaluated in randomized trials using CT and SSRI. Our aim was to evaluate whether one treatment is more effective than the other and whether combined treatment is more effective than the single treatments.

METHODS

A total of 102 patients were randomly assigned to paroxetine, CT, the combination of CT and paroxetine, or pill placebo. The medication treatment lasted 26 weeks. Of the 102 patients, 54% fulfilled the criteria for an additional diagnosis of avoidant personality disorder. Outcomes were measured at posttreatment and 12-month follow-up assessments.

RESULTS

CT was superior to paroxetine alone and to pill placebo at the end of treatment, but it was not superior to the combination treatment. At the 12-month follow-up, the CT group maintained benefits and was significantly better than placebo and paroxetine alone, whereas there were no significant differences among combination treatment, paroxetine alone, and placebo. Recovery rates at 12 months were much higher in the CT group (68%) compared to 40% in the combination group, 24% in the paroxetine group, and 4% in the pill placebo group.

CONCLUSIONS

CT was the most effective treatment for SAD at both posttreatment and follow-up compared to paroxetine and better than combined treatment at the 12-month follow-up on the Liebowitz Social Anxiety Scale. Combined treatment provided no advantage over single treatments; rather there was less effect of the combined treatment compared to CT alone.

摘要

背景

治疗社交焦虑障碍(SAD)最有效的方法是选择性 5-羟色胺再摄取抑制剂(SSRIs)和认知疗法(CT)。提倡对 SAD 进行联合治疗,但尚未在使用 CT 和 SSRI 的随机试验中进行评估。我们的目的是评估一种治疗方法是否比另一种更有效,以及联合治疗是否比单一治疗更有效。

方法

共有 102 名患者被随机分配至帕罗西汀、CT、CT 和帕罗西汀联合治疗或安慰剂组。药物治疗持续 26 周。在 102 名患者中,54%符合附加诊断回避型人格障碍的标准。在治疗结束时和 12 个月随访评估时测量结局。

结果

CT 在治疗结束时优于单独使用帕罗西汀和安慰剂,但不如联合治疗。在 12 个月的随访中,CT 组保持了获益,并且明显优于安慰剂和单独使用帕罗西汀,而联合治疗、单独使用帕罗西汀和安慰剂之间没有显著差异。在 12 个月时,CT 组的恢复率(68%)明显高于联合治疗组(40%)、帕罗西汀组(24%)和安慰剂组(4%)。

结论

与帕罗西汀相比,CT 在治疗结束时和随访时都是治疗 SAD 的最有效方法,在 Liebowitz 社交焦虑量表上,12 个月随访时 CT 优于联合治疗。联合治疗与单一治疗相比没有优势;实际上,联合治疗的效果不如单独使用 CT。

相似文献

1
Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial.帕罗西汀、认知疗法或两者联合治疗伴或不伴回避型人格障碍的社交焦虑障碍:一项随机临床试验。
Psychother Psychosom. 2016;85(6):346-356. doi: 10.1159/000447013. Epub 2016 Oct 15.
2
Group schema therapy versus group cognitive behavioral therapy for patients with social anxiety disorder and comorbid avoidant personality disorder: A randomized controlled trial.社交焦虑障碍共病回避型人格障碍患者的团体图式治疗与团体认知行为治疗的比较:一项随机对照试验。
J Anxiety Disord. 2024 Jun;104:102860. doi: 10.1016/j.janxdis.2024.102860. Epub 2024 Apr 3.
3
Personality change during depression treatment: a placebo-controlled trial.抑郁症治疗期间的人格变化:一项安慰剂对照试验。
Arch Gen Psychiatry. 2009 Dec;66(12):1322-30. doi: 10.1001/archgenpsychiatry.2009.166.
4
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.帕罗西汀治疗广泛性社交恐惧症(社交焦虑症):一项随机对照试验。
JAMA. 1998 Aug 26;280(8):708-13. doi: 10.1001/jama.280.8.708.
5
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.文拉法辛缓释剂与安慰剂及帕罗西汀治疗社交焦虑障碍的比较
Arch Gen Psychiatry. 2005 Feb;62(2):190-8. doi: 10.1001/archpsyc.62.2.190.
6
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.帕罗西汀、氯米帕明及认知疗法治疗惊恐障碍
J Clin Psychiatry. 1999 Dec;60(12):831-8. doi: 10.4088/jcp.v60n1205.
7
A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.帕罗西汀与安慰剂治疗广泛性社交焦虑障碍的随机、双盲、固定剂量对照研究
J Clin Psychiatry. 2002 Jan;63(1):66-74. doi: 10.4088/jcp.v63n0113.
8
A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.一项关于帕罗西汀辅助治疗对仅接受认知行为疗法治疗未成功的惊恐障碍患者影响的随机、双盲、安慰剂对照研究。
J Clin Psychiatry. 2002 Sep;63(9):772-7. doi: 10.4088/jcp.v63n0904.
9
Group schema therapy versus group cognitive behavioral therapy for social anxiety disorder with comorbid avoidant personality disorder: study protocol for a randomized controlled trial.团体模式疗法与团体认知行为疗法治疗合并回避型人格障碍的社交焦虑障碍:一项随机对照试验的研究方案
Trials. 2016 Oct 8;17(1):487. doi: 10.1186/s13063-016-1605-9.
10
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.氯硝西泮与帕罗西汀联合用药对比帕罗西汀单药治疗广泛性社交焦虑障碍的双盲、安慰剂对照评估
J Clin Psychiatry. 2004 Feb;65(2):244-8.

引用本文的文献

1
Traditional Chinese Medicine in the Management of Anxiety Disorders: A Narrative Review of Theoretical Foundations, Clinical Applications, and Modern Integrative Approaches.中医对焦虑症的管理:理论基础、临床应用及现代综合方法的叙述性综述
Neuropsychiatr Dis Treat. 2025 Jun 18;21:1215-1233. doi: 10.2147/NDT.S535646. eCollection 2025.
2
The impact of stress on sleep quality: a mediation analysis based on longitudinal data.压力对睡眠质量的影响:基于纵向数据的中介效应分析
Front Psychol. 2024 Oct 21;15:1431234. doi: 10.3389/fpsyg.2024.1431234. eCollection 2024.
3
Interpersonal neural synchrony and mental disorders: unlocking potential pathways for clinical interventions.
人际神经同步与精神障碍:揭示临床干预的潜在途径
Front Neurosci. 2024 Mar 11;18:1286130. doi: 10.3389/fnins.2024.1286130. eCollection 2024.
4
Sudden gains in face-to-face and internet-based cognitive therapy for social anxiety disorder.面对面和基于互联网的认知疗法治疗社交焦虑障碍的突然收益。
Behav Res Ther. 2023 Jul;166:104334. doi: 10.1016/j.brat.2023.104334. Epub 2023 May 11.
5
Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety.评估大麻二酚治疗社交焦虑症疗效的人体研究的系统文献综述。
Psychiatry Res Commun. 2022 Dec;2(4). doi: 10.1016/j.psycom.2022.100074. Epub 2022 Sep 13.
6
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.低剂量口服大麻二酚的安全性和疗效:证据评估。
Clin Transl Sci. 2023 Jan;16(1):10-30. doi: 10.1111/cts.13425. Epub 2022 Oct 19.
7
Antidepressants for social anxiety disorder: A systematic review and meta-analysis.抗抑郁药治疗社交焦虑障碍:系统评价和荟萃分析。
Neuropsychopharmacol Rep. 2022 Dec;42(4):398-409. doi: 10.1002/npr2.12275. Epub 2022 Jul 18.
8
More than doubling the clinical benefit of each hour of therapist time: a randomised controlled trial of internet cognitive therapy for social anxiety disorder.将治疗师每小时的临床获益提高一倍以上:互联网认知疗法治疗社交焦虑障碍的随机对照试验。
Psychol Med. 2023 Aug;53(11):5022-5032. doi: 10.1017/S0033291722002008. Epub 2022 Jul 15.
9
Psychiatry Meets Cardiology: A Case Report on the Need for Mental Health Assessment in the Evaluation of Cardiovascular Symptoms.精神病学与心脏病学的交汇:一则关于心血管症状评估中精神健康评估必要性的病例报告。
Case Rep Psychiatry. 2022 Apr 21;2022:5415196. doi: 10.1155/2022/5415196. eCollection 2022.
10
A scoping review of the use of cannabidiol in psychiatric disorders.精神障碍中使用大麻二酚的范围综述。
Psychiatry Res. 2022 Feb;308:114347. doi: 10.1016/j.psychres.2021.114347. Epub 2021 Dec 20.